Multiple myeloma (MM) remains an incurable disease by conventional therapy. MM tumor cells evade the immune system and can induce immunosuppression by producing immunomodifying agents such as TGF-β, FasL, vascular endothelial growth factor and Muc-1. In the present study, we show that bone marrow cells from a patient suffering from MM IgG/k type, stage IIIA, when cultured, expressed granzyme B and perforin, normally expressed exlusively by cytotoxic T cells (CTLs) and natural killer (NK) cells. In addition, phenotypic analysis revealed that the cultured cells were activated antigen-presenting cells with NK targeting capacity. We propose that expression of these cytolytic enzymes may constitute an additional adoptive mechanism by the tumor cells to actively destroy the host immune effector cells.

Keywords:
Multiple myeloma, Apoptosis, Cytotoxicity, Granzyme B, Perforin, Immunoparesis
1.
Hallek PM, Bergsagel L, Anderson K: Multiple myeloma: Increasing evidence for a multiple transformation process. Blood 1998;91:3–21.
2.
Urashima M, Chen BP, Chen S, Pinkus GS, Bronson RT, Dedera DA, Hoshi Y, Teoh G, Ogata A, Treon SP, Chauhan D, Anderson KC: The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 1997;90:754–765.
3.
Kyrtsonis MC, Mouzaki A, Maniatis A: Mechanisms of polyclonal hypogammaglobulinaemia in multiple myeloma (MM). Med Oncol 1999;16:73–77.
4.
Kornblau SM, Thall PF, Estrov Z, Walterscheid M, Patel S, Theriault A, Keating MJ, Kantarjian H, Estey E, Andreeff M: The prognostic impact of Bcl2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res 1999;5:1758–1766.
5.
Shi L, Kam CM, Powers JC, Aebersold R, Greenberg AH: Purification of three cytotoxic lymphocyte granule serine proteases that induce apoptosis through distinct substrate and target cell interactions. J Exp Med 1992;176:1521–1529.
6.
Podack ER, Young JD, Cohn ZA: Isolation and biochemical purification and functional characterization of perforin 1 from cytolytic T-cell granules. Proc Natl Acad Sci USA 1985;82:8629–8633.
7.
Masson D, Tschopp J: Isolation of a lytic, pore-forming protein (perforin) from cytolytic T-lymphocytes. J Biol Chem 1985;260:9069–9072.
8.
Podack ER: Execution and suicide: Cytotoxic lymphocytes enforce Draconian laws through separate molecular pathways. Curr Opin Immunol 1995;7:11–16.
9.
Stepp SE, Mathew PA, Bennett M, Basile GS, Kumar V: Perforin: More than just an effector molecule. Immunol Today 2000;21:254–256.
10.
Heiben JA, Barry M, Motyka B, Bleackley RC: Granzyme B-induced loss of mitochondrial inner membrane potential (ΔΨm) and cytochrome c release are caspase independent. J Immunol 1999;163:4683–4693.
11.
Chomczynski P, Sacchi N: Single-step method for RNA isolation by acid guanidinium thiocyanate-phenol-chlorophorm extraction. Anal Biochem 1987;162:156–159.
12.
Mouzaki A, Kindler V, Bowers N, Doucet A, Melachrinou M, Kyrtsonis MC, Maniatis A: Cytokine gene expression in a case of B-cell chronic lymphocytic leukemia (B-CLL) with an unusual expansion of T cells at presentation. Mol Biol Hematop 1996;5:237–246.
13.
Tsujimoto Y, Croce CM: Analysis of the structure, transcripts and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986;83:5214–5218.
14.
Ohminami H, Yasukawa M, Kaneko S, Yakushijin Y, Abe Y, Kasahara Y, Ishida Y, Fujita S: Fas-independent and non-apoptotic cytotoxicity mediated by a human CD4+ T-cell clone directed against an acute myelogenous leukemia-associated DEK-CAN fusion peptide. Blood 1999;93:925–935.
15.
Haddad P, Clement MV, Bernard O, Larsen CJ, Degos L, Sasportes M, Mathieu D: Structural organization of the hCTLA-1 encoding human granzyme B. Gene 1990;87:265–271.
16.
Griffiths GM, Isaaz S: Granzymes A and B are targeted to the lytic granules of lymphocytes by the mannose-6-phosphate receptor. J Cell Biol 1993;120:885–896.
17.
Mouzaki A, Rungger D, Tucci A, Doucet A, Zubler RH: Occurrence of a silencer of the interleukin-2 gene in naive but not in memory resting T helper lymphocytes. Eur J Immunol 1993;23:1469–1474.
18.
Cook G, Campbell JDM: Immune regulation in multiple myeloma: The host-tumor conflict. Blood Rev 1999;13:151–162.
19.
Tang H, Matthes T, Carballido-Perrig N, Zubler RH, Kindler V: Differential induction of T cell cytokine mRNA in Epstein-Barr virus-transformed B cell clones: Constitutive and inducible expression of interleukin-4 mRNA. Eur J Immunol 1993;23:899–903.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.